Insulin Pen Injectors: Comprehensive Classification, Treatment Regimens, and Clinical Best Practices

From Device Selection to Optimized Glycemic Control — An Evidence-Based Guide

Diabetes mellitus affects hundreds of millions worldwide, and insulin therapy remains a cornerstone for type 1 and many type 2 diabetes patients. Among the various delivery methods, insulin pen injectors have revolutionized self-administration — offering greater accuracy, convenience, and patient compliance compared to traditional vials and syringes. This article provides a technically rigorous overview of insulin pen classification by function and manufacturer, followed by a detailed breakdown of common insulin pen treatment regimens (30R, 50R, N, R). Healthcare professionals, patients, and digital health content curators will find actionable insights grounded in clinical practice.

---

Part 1: Classification of Insulin Pens by Functional Use

Selecting the right insulin pen device is the first step toward reliable dosing. Based on reusability, insulin pens fall into two primary categories.

1. Reusable Insulin Pens (Durable Pens)

Reusable insulin pens are designed for long‑term use — often lasting for many years or even a lifetime. The patient inserts a replaceable 3 mL insulin cartridge (typically 300 units). When the cartridge is empty, it is discarded and replaced with a new one, while the pen body is retained.

Key characteristics:

• Cost‑effective over time – Higher upfront cost but lower recurring expense.
• Precise dosing – Most models offer 1‑unit or 0.5‑unit increments.
• Wide availability – In many countries (including China), reusable pens are readily available from brands such as Novo Nordisk (NovoPen), Eli Lilly (HumaPen), and Sanofi (ClikSTAR).
• Example brands – Becton Dickinson insulin pen (see manufacturer classification below), NovoPen 6 with memory function.

2. Disposable Insulin Pens (Prefilled Pens)

Disposable pens come pre‑filled with insulin. Once the cartridge is empty (or after a specified number of days in use), the entire pen is discarded. A new pen is required for the next refill.

Key characteristics:

• Simple and hygienic – No need to load cartridges; reduces contamination risk.
• Ideal for low‑dexterity patients – Often easier to handle.
• Geographic variation – Common in North America and Europe; less common in China (as noted in the source document).
• Example – FlexPen (Novo Nordisk), SoloStar (Sanofi), KwikPen (Eli Lilly).

Clinical note: While disposable pens offer convenience, they generate more medical waste. For environmentally conscious patients or those using multiple insulin types, reusable pens may be preferable.

---

Part 2: Classification of Insulin Pens by Manufacturer

Different manufacturers produce pens with distinct ergonomics, dose dialing mechanisms, and cartridge interfaces. Patients and clinicians must read the device’s instruction manual and receive proper training from diabetes educators before first use.

Fabricante	Representative Pen Model	Principais recursos
Becton Dickinson (BD)	BD Insulin Pen	High‑precision dosing; compatible with BD micro‑fine needles; reusable design
Owen Mumford	Autopen (classic model)	Easy‑squeeze push‑button; available in 1‑unit or 2‑unit increments; reusable
Novo Nordisk	NovoPen 6 / Echo Plus	Smart pens with memory / Bluetooth connectivity; half‑unit dosing (Echo)
Sanofi	ClikSTAR / JuniorSTAR	Large dose display; low‑force injection; junior version with 0.5‑unit steps
Eli Lilly	HumaPen Luxura HD	Half‑unit dosing; metal body; durable construction

Important: Insulin cartridges from different brands are not universally interchangeable. Always match the cartridge brand to the pen type. For example, a NovoPen requires Novo Nordisk 3 mL cartridges.

---

Part 3: Insulin Pen Treatment Regimens — Clinical Approaches

The source document outlines four core regimens based on premixed insulin ratios or single‑type insulins. These are widely used in clinical practice, especially in Asia where premixed insulins dominate.

Regimen 1: Premixed Insulin 30R (Most Common)

Insulin composition: 30% short‑acting insulin (R) + 70% intermediate‑acting insulin (NPH, or N).
Typical product name: Novolin 30R, Humulin 30/70, or generic 30R penfill. Each cartridge contains 300 units.

Injection schedule: Twice daily — before breakfast and before dinner.

Mechanism of action:

• Morning dose (2/3 of total daily dose) – The 30% short‑acting component controls post‑breakfast glucose; the 70% NPH covers lunch and afternoon glucose.
• Evening dose (1/3 of total daily dose) – Short‑acting component controls post‑dinner glucose; NPH provides basal coverage through the night and early morning.

Dose titration: Adjust by 2 units per injection based on self‑monitored blood glucose (SMBG) levels. Typically, breakfast dose is twice the dinner dose (e.g., 20 units AM / 10 units PM).

Advantages: Simple two‑injection regimen; good for patients with predictable meal schedules.
Limitations: May not provide optimal overnight basal coverage; lunchtime hypoglycemia risk if midday meal is delayed.

Regimen 2: Premixed Insulin 50R

Insulin composition: 50% short‑acting (R) + 50% intermediate (NPH).
Example product: Novolin 50R (Novo Nordisk).

When to use: For patients with persistently high postprandial glucose despite 30R therapy. The higher proportion of short‑acting insulin (50% vs 30%) provides stronger control of meal‑time spikes.

Injection schedule: Same twice‑daily pattern (breakfast + dinner).

Dose distribution: Often also 2/3 AM, 1/3 PM, but can be individualized.

Potential drawbacks: Because the intermediate component is only 50% (vs 70% in 30R), coverage for inter‑prandial periods (mid‑morning, mid‑afternoon, and overnight) may be insufficient. Monitor for late‑night hypoglycemia or fasting hyperglycemia.

Clinical pearl: 50R is particularly useful in East Asian populations where post‑meal glucose excursions tend to be more pronounced.

Regimen 3: Intermediate‑Acting Insulin N (NPH) Alone

Insulin composition: 100% NPH insulin (e.g., Novolin N, Humulin N). No short‑acting component.

Indications:

1. Add‑on to oral agents in type 2 diabetes – For patients with inadequate basal control, one or two daily NPH injections may be added to metformin or sulfonylureas.

• Example: Bedtime NPH to control fasting glucose.

1. Combination with a separate short‑acting insulin (R) – The patient uses an NPH pen e a separate R pen to mimic basal‑bolus therapy.

Injection schedule options:

• Once daily (bedtime) – mild fasting hyperglycemia.
• Twice daily (breakfast + bedtime) – more consistent basal coverage.

Limitations: NPH has a pronounced peak (4–6 hours) and variable absorption. It does not control meal‑related glucose spikes when used alone. Do not use NPH monotherapy for prandial coverage.

Regimen 4: Short‑Acting Insulin R Alone

Insulin composition: 100% regular human insulin (e.g., Novolin R, Humulin R). Onset ~30 min, peak 2–4 hours, duration ~6–8 hours.

Typical use: As part of a basal‑bolus regimen — inject R before each meal (breakfast, lunch, dinner). To cover nocturnal basal needs, patients must either:

• Add a bedtime NPH injection, or
• Use a separate NPH pen in the morning and evening.

Practical injection schedule (R + NPH combination):

• Breakfast: R (covers breakfast)
• Lunch: R (covers lunch)
• Dinner: R (covers dinner)
• Bedtime: NPH (basal coverage overnight)

Important note: Short‑acting R must be injected 30 minutes before meals to match glucose rise — a significant inconvenience compared to rapid‑acting analogs (e.g., lispro, aspart). However, R insulin is still widely used in resource‑limited settings due to lower cost.

---

Conclusão

Insulin pen injectors — whether reusable or disposable, from Becton Dickinson or Owen Mumford — have transformed diabetes care. Understanding the functional and manufacturer classifications ensures patients select the right device. Equally important, mastering premixed regimens (30R, 50R) and single‑insulin regimens (N, R) enables optimal glycemic control.

---

For medical professionals: This information is for educational purposes. Individual treatment decisions must be made by qualified practitioners based on patient‑specific factors.

Last updated: May 2026
Sources: Clinical practice guidelines; manufacturer product information (Novo Nordisk, Eli Lilly, Sanofi, BD, Owen Mumford); diabetes treatment protocols from leading endocrine societies.